Patient P-02410

Synthetic patientMETA-24 · Day 170 · 35–44 · M · baseline S01Open companion preview

Therapy response

Improving

Tolerance

Favorable

GI state

Stable

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

58%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S01
Day 72 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 75 GI-04 recommended — GI Support Protocol GI-04
Day 76 Patient accepted — Started GI-04 in the companion
Day 84 GI symptom burden −32% vs expected — GI Support Protocol GI-04
Day 90 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 72.

Primary contributors, last 14 days

Inflammatory activity+8
GI instability+4
Treatment adherence+3
Toxicity+3
Nutritional resilience-2

What helped?

GI Support Protocol GI-04Day 75
Result: symptom burden −32%

LIFE OS recommendation

Monitoring Escalation ME-01

73%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 27/100
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 50
Autonomic recovery ↓40
- Wearable3,445 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓30
- Daily logGI symptom score 53 and rising
- WearableSleep 6.0 h, below personal baseline

DNA

Fictional pharmacogenomic panel

CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.1 · butyrate capacity 27/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 56 ms
Sleep: 6.1 h
Steps: 3,686
Resting HR: 67 bpm

Daily log: GI score 53, nutritional resilience 44, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02504	51%	S14	GI-04	improved	52
P-02401	49%	S14	GI-04	improved	49
P-02018	48%	S01	GI-04	improved	46
P-02670	48%	S14	SC-12	improved	45
P-02002	47%	S14	GI-04	improved	47
P-02328	47%	S14	GI-04	improved	42
P-02103	46%	S14	GI-04	improved	46
P-02535	46%	S14	SC-12	improved	50
P-02316	45%	S14	GI-04	improved	51
P-02516	44%	S14	SC-12	improved	51
P-02176	43%	S14	GI-04	improved	52
P-02255	43%	S14	GI-04	improved	43